Protection against liver damage by HGF
AssigneeGenentech, Inc.
InventorsFilip Roos, Ralph Schwall
Life of this patent
Estimating the term…
Abstract
The present invention provides methods for preventing occurrence or progression of liver damage using hepatocyte growth factor. In the methods, a preventatively effective amount of the hepatocyte growth factor is administered to the patient. The hepatocyte growth factor can be administered, for instance, prior to administering a hepatotoxic therapy to the patient. The hepatocyte growth factor can further be administered with activin or transforming growth factor-beta to prevent liver damage. Compositions comprising hepatocyte growth factor and activin antagonist or transforming growth factor-beta antagonist are also provided by the invention.
Claims15
A method for preventing liver damage in a patient due to exposure to a hepatotoxic agent, the method comprising:
- administering hepatocyte growth factor to the patient, wherein said hepatocyte growth factor effectively prevents liver damage due to exposure to the hepatotoxic agent, and wherein said administering is prior to known liver damage in the patient.
A method for preventing liver damage in a patient, the method comprising:
- administering hepatocyte growth factor to the patient concurrent with exposure of the patient to a hepatotoxic agent, wherein said administering is prior to diagnosis of liver damage in the patient.
A method for preventing liver damage in a patient, the method comprising:
- administering hepatocyte growth factor to the patient prior to exposure of the patient to a hepatotoxic agent, wherein said hepatocyte growth factor effectively prevents liver damage due to exposure to the hepatotoxic agent.
A method for preventing liver damage in a patient, the method comprising:
- administering to the patient hepatocyte growth factor, wherein said administering is after exposure of the patient to a hepatotoxic agent but prior to known liver damage in the patient.
A method for the treatment of a patient comprising:
- administering to a patient a biologically effective dose of a therapeutic agent and HGF, wherein said therapeutic agent is activin, wherein said HGF effectively prevents liver damage due to exposure to activin.
Dependencies are inferred from the claim text.